Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.9K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Modular and Scalable FPGA Platform for Intelligent, High-Throughput Image-Activated Cell Sorting.

Cytometry. Part A : the journal of the International Society for Analytical Cytology·2026
Same author

GalNAc-conjugated siRNA targeting C/EBPβ reverses metabolic dysfunction and restores liver homeostasis in a murine MASLD model.

Molecular therapy. Nucleic acids·2026
Same author

Glutathione-activatable bola dendrimers mediate tumor-specific cytosolic siRNA delivery <i>via</i> dynamic thiol-disulfide exchange.

Biomaterials science·2026
Same author

Self-assembling dendrimer nanoparticles in cancer therapy.

Nanomedicine (London, England)·2026
Same author

Development of conditional-siRNA programmable riboswitch for targeting adverse cardiac remodeling.

Molecular therapy. Nucleic acids·2025
Same author

Cryo-EM structures reveal the PP2A-B55α and Eya3 interaction that can be disrupted by a peptide inhibitor.

The Journal of biological chemistry·2025

Related Experiment Video

Updated: Mar 12, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.5K

Aptamers as targeted therapeutics: current potential and challenges.

Jiehua Zhou1, John Rossi1,2

  • 1Department of Molecular and Cellular Biology, Beckman Research Institute of City of Hope, 1500 E. Duarte Rd, Duarte, California 91010, USA.

Nature Reviews. Drug Discovery
|November 4, 2016
PubMed
Summary

Nucleic acid aptamers offer advantages over antibodies for drug delivery but face challenges. Recent advances are paving the way for clinical use of these promising therapeutics.

More Related Videos

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins
11:34

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

7.2K
Selection of Aptamers for Amyloid &#946;-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

20.0K

Related Experiment Videos

Last Updated: Mar 12, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.5K
Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins
11:34

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

7.2K
Selection of Aptamers for Amyloid &#946;-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

20.0K

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Drug Delivery

Background:

  • Nucleic acid aptamers, or 'chemical antibodies', mimic antibody functions.
  • They possess advantages like small size, stability, and low immunogenicity.
  • Aptamers can be internalized by cells, enabling targeted delivery of therapeutics.

Purpose of the Study:

  • To review the challenges hindering clinical translation of therapeutic aptamers.
  • To highlight recent advancements and clinical developments in aptamer therapeutics.
  • To discuss the renewed impetus for aptamer-based therapies.

Main Methods:

  • Literature review of aptamer technology and clinical trials.
  • Analysis of inherent physicochemical characteristics and safety data.
  • Discussion of technological innovations in aptamer development.

Main Results:

  • Aptamers present significant advantages over traditional antibodies.
  • Key challenges include physicochemical properties and limited safety data.
  • Recent progress shows promise for overcoming these hurdles.

Conclusions:

  • Despite challenges, aptamers hold significant therapeutic potential.
  • Technological advancements are driving progress in aptamer clinical translation.
  • Aptamers are poised to become a significant class of future therapeutics.